Viewpoint

Michal Brnušàk takes a look at the obstacles – and hopes – for commercialising research in Prague.

Anti-trust legislation, particularly involving raids at dawn, is no way to improve productivity in the pharmaceutical industry, says Nuala Moran.

As Framework Programme 7 fires up, Europe’s auditors throw on some cold water. Nuala Moran wonders how we will assess whether it has all been worthwhile.

The spin-out tag makes university start-ups look weak and vulnerable, says Philip Sharpe from QinetiQ, one of Europe’s largest technology commercialisation companies.

Science|Business launches a series of news and events to prompt debate on a vital policy question: How do you encourage enterprise in science?

Want to improve R&D policy? The European Commission is creating a new advisory panel. Send in your nominations.

What is the best way for the EU to spend its R&D money? An unusual debate at the European Commission provides insights.

The continuing argument over first-generation GMcrops has created a huge roadblock to more refined agbiotech developments, says Nuala Moran

A call for new ideas to shake up the Brussels policy world.

Despite the Nobel-induced champagne now flowing in Berlin, Jülich, Paris and Cardiff, the fact remains that Europe has a fundamental problem in the quality of its science.